Clinical trials: HEPATITIS C VIRUS CHRONIC INFECTION
Hepatitis C
TMC647055HPC1001 - First-in-human Trial to Examine Safety, Tolerability and Pharmacokinetics (How the Drug is Absorbed Into the Bloodstream) of Increasing Single Oral Doses and of Increasing Repeated Oral Doses of TMC647055 in Healthy Volunteers and in Hepatitis C Virus Infected Patients
The purpose of this study is to assess the safety and tolerability of TMC647055 both after increasing single oral doses from 100 mg up to maximum 3000 mg in fed conditions, and after multiple oral doses in fed conditions at…
- Trial name
- NCT01202825
- Testing
- TMC647055, TMC435
- Where
- Belgium
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Hepatitis C, Chronic, Opioid Dependence, on Agonist Therapy
Integrated Treatment of Hepatitis C Virus Infection
INTRO-HCV is a multicentre randomised controlled clinical trial that will compare the efficacy of integrated treatment of chronic hepatitis C virus infection (HCV) within medically assisted rehabilitation (MAR) clinics providing…
- Trial name
- INTRO-HCV (NCT03155906)
- Testing
- Health care delivery
- Where
- 2 sites in Norway
- Volunteers
- 298 people
- Sponsor
- Haukeland University Hospital
Hepatitis C Virus (HCV)
Sofosbuvir/Velpatasvir/Voxilaprevir Salvage Therapy in Hepatitis C Patients Who Relapsed After DAA Treatment
This multicenter study evaluates the effectiveness and safety of a 12-week regimen of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C who relapsed after prior direct-acting antiviral therapy.
- Trial name
- NCT07565948
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Xiangya Hospital of Central South University
HIV, Hepatitis C
Chronic Hepatitis Intervention Project for Drug Users
The purpose of this study is to determine if a 6-session motivational interviewing intervention is more effective than a 6-session educational intervention at reducing behaviors that may lead to infection, transmission, and…
- Trial name
- NCT00596843
- Testing
- Motivational interviewing, Educational intervention
- Where
- United States
- Volunteers
- 851 people, healthy volunteers welcome
- Sponsor
- National Institute on Drug Abuse (NIDA)
Chronic Hepatitis C
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Participants With Chronic Hepatitis C
The interferon-free combination regimen of paritaprevir/ritonavir/ombitasvir with or without dasabuvir (ABBVIE REGIMEN) ± ribavirin (RBV) for the treatment of chronic hepatitis C (CHC) has been shown to be safe and effective in…
- Trial name
- NCT02725866
- Testing
- Paritaprevir/ritonavir/ombitasvir, Dasabuvir, Ribavirin
- Volunteers
- 216 people
- Sponsor
- AbbVie
Hepatitis C Infection
Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin)
The purpose of this study is to identify 1 or more doses of daclatasvir, which when used in combination with pegylated interferon alpha and ribavirin, are safe and demonstrate sufficient anti-hepatitis C virus activity.
- Trial name
- NCT00874770
- Testing
- Daclatasvir, Peginterferon alpha-2a, ribavirin
- Where
- 14 sites in United States, France
- Volunteers
- 74 people
- Sponsor
- Bristol-Myers Squibb
Psychiatric Disorders, Cognitive Impairment
Impact on QoL and Cognitive Functioning of New Antiviral Therapies in Subjects With Chronic Hepatitis HCV-related
Chronic hepatitis HCV-related is the most common cause of chronic liver disease in Italy. Patients with chronic hepatitis C present a prevalence of depressive disorders higher than that of the general population; moreover, it has…
- Conditions
- Psychiatric Disorders, Cognitive Impairment, Chronic Hepatitis c
- Trial name
- NCT03313154
- Testing
- Neuropsychiatric screening
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Azienda Ospedaliero Universitaria di Cagliari
Hepatitis C Virus Infection
Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis
The primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of therapy with sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) in adults with chronic hepatitis C virus (HCV)…
- Trial name
- NCT04112303
- Testing
- SOF/VEL
- Where
- 22 sites in Japan
- Volunteers
- 37 people
- Sponsor
- Gilead Sciences
Hepatitis C, Chronic
A Study of The Relationship Between Drop in Hemoglobin and Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a)
This open-label, multicenter, phase IV study will evaluate the relationship between the drop in hemoglobin levels and sustained virological response in patients with chronic hepatitis C genotype 1 treated with Copegus (ribavirin)…
- Trial name
- NCT01585324
- Testing
- peginterferon alfa-2a [Pegasys], ribavirin [Copegus]
- Where
- Czechia
- Volunteers
- 30 people
- Sponsor
- Hoffmann-La Roche
Cirrhosis, Chronic Hepatitis C
Efficacy and Safety of Viusid in Patients With Hepatic Cirrhosis Secondary to Hepatitis C Virus Infection.
The purpose of the study is to evaluate whether Viusid, a nutritional supplement, reduce the mortality and the complications (ascites, spontaneous bacterial peritonitis, hepatorenal syndrome, hepatic encephalopathy…
- Trial name
- NCT00502086
- Testing
- Viusid (nutritional supplement)
- Where
- Cuba
- Volunteers
- 100 people
- Sponsor
- Catalysis SL
Chronic Hepatitis C
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C
The interferon-free combination regimen of paritaprevir/r - ombitasvir with or without dasabuvir (ABBVIE REGIMEN) ± ribavirin (RBV) for the treatment of chronic hepatitis C (CHC) has been shown to be safe and effective in…
- Trial name
- 3DUTCH (NCT02817594)
- Where
- 9 sites in Netherlands
- Volunteers
- 51 people
- Sponsor
- AbbVie
Hepatitis C, Chronic
Evaluation of Multiple HCV Diagnosis Pathways for Efficacy, Cost Effectiveness and Cure in NHS Tayside
EVERYONES HCV is a retrospective review of all previous Hepatitis C (HCV) testing and diagnosis in NHS Tayside. The aim of this study is to analyse and compare the different Hepatitis C diagnostic pathways with a view to…
- Trial name
- NCT03513796
- Where
- United Kingdom
- Volunteers
- 1,949 people
- Sponsor
- NHS Tayside
Hepatitis C, Chronic
Buprenorphine Versus Methadone Maintenance in Hepatitis C Patients Receiving Peg-Intron and Rebetol (Study P04279)(TERMINATED)
This randomized, single-center, controlled study is designed to evaluate the safety, tolerability, and efficacy of treatment with Peg-Intron with Rebetol in methadone or buprenorphine maintenance patients with hepatitis C.
- Trial name
- NCT00279565
- Testing
- buprenorphine, methadone, pegylated interferon alfa-2b plus ribavirin
- Volunteers
- 128 people
- Sponsor
- Indivior Inc.
HIV Infections, Sexually Transmitted Infection
User-friendly HIV Testing and Counseling Services
Multicenter cohort study of individuals reporting behavioral risks of HIV acquisition, recruited among those presenting for testing for HIV and other sexually transmitted infections.
- Conditions
- HIV Infections, Sexually Transmitted Infection, Hepatitis B, Chronic, Hepatitis C
- Trial name
- NCT04585165
- Where
- 6 sites in Thailand
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Institut de Recherche pour le Developpement
Hepatitis C, Chronic, Liver Cirrhosis
Inhibition of Disease Progression in Hepatitis C-infected Patients With Compensated Liver Cirrhosis (P03811) (COMPLETED)
The objective of the study is to evaluate the superiority of treatment with PegIntron and Rebetol over no antiviral therapy (control group) in subjects with chronic hepatitis C and type C compensated cirrhosis.
- Trial name
- NCT00811967
- Testing
- PegIntron (peginterferon alfa-2b; SCH 54031), Rebetol (ribavirin; SCH 18908)
- Volunteers
- 50 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C
Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care
The purpose of this study is to determine whether BMS-650032 and BMS-790052 in combination alone, together with Ribavirin, or together with Interferon and Ribavirin are effective in the treatment of Hepatitis C in patients who…
- Trial name
- NCT01012895
- Testing
- BMS-790052, BMS-650032, Pegylated-interferon alfa-2a
- Where
- 18 sites in United States, France and 1 more
- Volunteers
- 215 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C Chronic
Drug Utilization of Boceprevir and Clinical Management of Health Outcomes of Interest in Chronic Hepatitis C Participants (P08518)
This is an observational prospective follow-up study to assess the utilization of boceprevir and the management of pre-specified health outcomes of interest (HOIs) under conditions of routine clinical care in participants with…
- Trial name
- NCT01544582
- Volunteers
- 713 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis c
The Tolerability and Pharmacokinetics Study of HEC74647PA Capsule in Healthy Adult Subjects
The Tolerability and Pharmacokinetics Study of HEC74647PA Capsule in Healthy Adult Subjects
- Trial name
- NCT03673696
- Testing
- HEC74647PA Capsule
- Where
- China
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Hepatitis C Virus Infection, Response to Therapy of
Clinical Trial to eLiminate HCV-infection in Treatment-naïve, Renally Impaired EgyptiAn Patients on Renal Dialysis, With Chronic Hepatitis C Genotype 4
Primary Efficacy Objective -To assess whether a 12-week treatment course with oral 50 mg elbasvir plus 100 mg grazoprevir given in a single daily dose to treatment-naïve patients with end-stage renal disease (ESRD) and infected…
- Trial name
- CLEAR-C4 (NCT03381859)
- Testing
- Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER]
- Where
- Egypt
- Sponsor
- University of Maryland, Baltimore
Hepatitis C, Chronic
Safety and Efficacy of Vaniprevir (MK-7009) With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) in Treatment-Experienced Hepatitis C Virus (HCV) Participants (MK-7009-009)
The purpose of this study is to test the safety, tolerability, and efficacy of 4 regimens of Vaniprevir + Peg-IFN and Ribavirin as compared to Placebo (PBO) + Peg-IFN/RBV.
- Trial name
- NCT00704405
- Testing
- Vaniprevir, Pegylated Interferon (Peg-IFN), Ribavirin (RBV)
- Volunteers
- 285 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.